Supernus Pharmaceuticals Inc. (SUPN)
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to break-even earnings per share a year ago.
What Makes Supernus (SUPN) a New Buy Stock
Supernus (SUPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -20.07% in 4 Weeks, Here's Why Supernus (SUPN) Looks Ripe for a Turnaround
Supernus (SUPN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2024 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2024 Earnings Call Transcript
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.02 per share a year ago.
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
On Tuesday, Supernus Pharmaceuticals, Inc. SUPN revealed the topline data from the Phase 2b study of SPN-820 in adults with treatment-resistant depression (TRD).
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade
Supernus (SUPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth
Supernus Pharmaceuticals recently posted better-than-expected Q3 results, and management also revised FY2024 guidance upward. The ADHD drug Qelbree, which was approved in 2021, is powering revenue growth, and reduced costs are benefiting the bottom line. The company also has a pristine balance sheet with just over $400 million in cash and marketable securities.
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Peter Vozzo – Investor Relations-ICR Healthcare Jack Khattar – Chief Executive Officer Tim Dec – Chief Financial Officer Conference Call Participants Andrew Tsai – Jefferies Stacy Ku – TD Cowen David Amsellem – Piper Sandler Operator Good afternoon, and welcome to Supernus Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode.
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
